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Abstract
BACKGROUND: Vitrification of cells or tissue at controlled cooling rates suitable for larger
volumes, and with reduced cryoprotectant toxicity. OBJECTIVE: To set out the current understanding
of the LiquidusTracking (LT) vitrification technique, and to discuss the challenges and benefits of
translating the method into laboratory protocols more generally applicable to meet requirements of
large volume and 3-D cryo-banking in the era of regenerative medicine. METHODS: By adding small
amounts of cryoprotectants at each step and subsequently cooling the sample just above its freezing
point before further increasing CPA concentration, cryoprotectant toxicity is minimized. RESULT:
CPA toxicity can be reduced by lowering the temperature. Different manual approaches to LT were
evaluated and further improved. CONCLUSIONS: Manual liquidus tracking is complicated and
exhibits potential high variability. Nevertheless, this approach offers the possibility of testing several
conditions simultaneously and could be used to pre-test conditions prior to automatic LT development.
Keywords: Vitrification, high cryoprotectant concentrations, Liquidus Tracking, liquidus curve
INTRODUCTION
Since the start of applied cryobiology by
the early pioneers (9, 10, 15), a wide range of
different cell types have been successfully
cyropreserved. This has become an important,
routine technology which facilitates exploitation
of cell biology for biotechnology, medicine or
fundamental research (18). These protocols have
been based largely on slow cooling protocols
after exposure of the cells to moderate
concentrations of cryoprotectants (CPA), with
cooling profiles typically in the range of -1°C to
-5°C/minute in volumes of 1-2 ml. However,
successful cryo-banking of larger structures,
such as tissues or organs, remains elusive, with
only rare claims of success (5), which have not
translated into robust repeatable systems. Even
dispersed, cellular systems, in volumes above 10
ml, have required sample size manipulation (e.g.
into a thin film volume format (11, 17)). The
problems are complex but can be divided into
two main areas. The first is the effect of the
location and compartmentalization of
extracellular ice during slow cooling of
3-dimensional structures. It has been long
recognised that ice formation driven by slow
cooling tends to proceed in non-uniform ways in
larger structures, with surface layers
experiencing ice nucleation first (16). The ice
tends to accumulate in whatever ‘non-structured’
liquid spaces are present within the tissue (such
as within small capillary blood vessels inside an
organ) (8), which act as growing ice foci
physically destroying the internal structure of the
tissue. The release of latent heat of ice formation
deeper inside the structure, causes uncontrolled
deviations of the cooling profile resulting
potential cryopreservation injury in selected
areas. The second major challenge is that, unlike
small volume cryopreservation, rewarming
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profiles of larger 3-dimensional structures can
only proceed at relatively slow rates because of
the low heat transfer properties. This compounds
the problems of ice crystal re-organisation and
growth in the extracellular ice loci within the
structure, and associated salt-induced hyper-
osmotic injury to the cells as they transition
across the higher subzero temperature range.
The technique of vitrification is
recognised as a successful way to avoid injury
from ice formation (15), and has grown in
popularity over the past 10 years in some areas
of cryo-banking such as cryo-storage of embryos
or oocytes (1, 2). By employing high CPA
concentrations (40% – 60% (w/v), successful
vitrification protocols can be widely applied (4,
7). However, there are specific requirements for
sample volumes (usually less than 200 µl) and
high cooling rates which must be imposed,
because even at these elevated CPA
concentrations, the ‘glassy state’ is achieved by
non-equilibrium glass transitions (2). Ultra-rapid
sample manipulation (of a few tens of seconds)
and cooling (in excess of -500°C/min) are
required to avoid toxic effects from the high
CPA concentrations, and kinetically favour the
glass transition; cooling at rates achievable with
larger 3-D structures (typically <-10°C/min)
invariably result in ice formation.
A different approach was suggested some
40 years ago by Farrant (6), based on
incrementally increasing the CPA concentration
in samples as cooling proceeded, to achieve high
enough CPA concentration to avoid ice
nucleation, with the required concentration at
each temperature being defined by the liquidus
curve of the mixture (Figure 1). Farrant’s
approach to prevent ice formation was
principally to avoid solution effects and to
maintain a constant electrolyte concentration
during the cooling process. Later the benefits of
avoiding ice per se became more evident. The
technique has been revived and more clearly
defined in recent years by Pegg’s group, and has
become known as Liquidus Tracking (LT) (14,
20). The main advantage of this method is the
diminution of CPA toxicity. The liquidus curve
(Figure 1) defines the equilibrium melting point
temperature for a given CPA mixture (i.e. the
highest sub-zero temperature at which ice
crystals and liquid can co-exist – and knowing
this fact it allows prediction of the lowest
subzero temperature which can be reached for
that given CPA mix without ice nucleating).
Cryoprotectants are less toxic at lower
temperatures (13, 21) and lower concentration.
By adding smaller amounts of CPA at each step
and subsequently cooling the sample to just
above its freezing point, toxicity is minimized
when attempting to achieve the very high CPA
concentrations required for vitrification. The
more increments used, the closer the sample can
be kept to the liquidus curve of its carrier CPA
solution. Due to reduced CPA toxicity, and
avoidance of ice nucleation, samples can be
vitrified without the necessity of fast cooling
rates, preferable for cooling large volumes, or
when longer exposure times are required to
allow for sufficient CPA penetration. An
example of this strategy is depicted in Figure 1.
Of equal importance for these larger volumes is
the warming process, which must be reversed in
a controlled (stepwise) fashion to dilute the high
CPA concentration whilst avoiding any
propensity for ice to nucleate.
This review sets out the current
understanding of LT, and discusses the practical
challenges and benefits of translating the method
into laboratory protocols which can be more
generally applied to meet requirements of cryo-
banking for large volume or 3-D structures in the
era of regenerative medicine.
The different technical approaches have
been developed using alginate-encapsulated liver
cells (AELC) as an illustrative model, and our
Figure 1. A schematic showing the Tm equilibrium
melting curve (liquidus) for Me2SO (modified from
Elford 1970 and Farrant 1965). Arrows indicate a
scheme for incremental addition of CPA to obtain the
lowest toxicity for a given CPA concentration. This is
achieved by decreasing the sample temperature to
just above the freezing point (dashed vertical line
above the liquidus curve) before adding more CPA
(solid horizontal line) to prevent freezing at lower
temperatures.
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group has wide experience in studying these (11,
12). AELC provide a scalable model of complex
3-D cell clusters similar to small tissues, but
which can be manipulated in volumes between 1
ml and 1 litre, suitable for investigating LT. The
chosen CPA was Me2SO, which has been the
CPA of choice for other recent LT studies (14,
20). The aim was to use AELC as a bio-object to
demonstrate the essential technical steps within
LT, which might then be tailored for laboratory
protocols, rather than provide an in-depth
assessment of cryo-banking AELC by this
approach.
APPROACHES TO LT OVER THE
PAST 30 YEARS
Elford and Walter (20) used the LT
approach to study the role of anionic
composition and pH of the carrier solution
needed to deliver the increasing concentrations
of CPA. Isolated strips of taenia coli muscle
were progressively cooled to -79°C with a final
concentration of 60% (w/v) Me2SO to prevent
freezing. Muscles showed slow recovery and
were severely damaged both functionally and
structurally when the incubation media had a
similar composition to that of Krebs solution,
but showed better recovery after rewarming
when potassium-rich media containing Na+, K+,
and Cl- were used. The degree of recovery was
dependent on the size of the anion, showing
better contractility of the muscles for
glycerophosphate, TES or PIPES (N-tris-
(hydroxymethyl)-methly-2 amino- or piperazine-
NN'-bis-2-ethanesulfonates) than for sulfate or
ethylsulfate derived anions. When using
potassium-rich PIPES media, recovery was
lower when the pH was reduced.
The technique lay dormant for many years
until it was revived by David Pegg and
colleagues (14,20). Pegg used the same protocol
as Elford and Walter (but with different
incubation times) for LT vitrification of articular
cartilage and found that damage was
predominantly associated with the formation of
ice during standard cryopreservation, which
supported the use of a vitrification protocol, but
CPA toxicity and the need for rapid warming
resulted in inadequate recovery. By using the LT
(equilibrium vitrification) approach, cartilage
was successfully recovered with good metabolic
activity (based on an incorporation of sulphate
into newly synthesized glycosaminoglycans
(GAGs) at 70% of that of fresh control
cartilage). The first experiments were carried out
using a Dow Corning oil bath for step-wise
cooling, and manual transfer of the samples to
increase CPA sufficiently to suppress ice
formation at the set temperatures; thereafter, a
controlled rate Planer freezer was used to
achieve continuously lowering temperatures
which could also be held at selected low
temperatures to allow for CPA equilibration. By
applying continuous stirring throughout the
process, a significant increase of GAG synthesis
to 87% of the corresponding fresh control values
was reached. Preservation of human knee joint
cartilage resulted in GAG synthesis of 70% and
ovine knee joint osteochondral dowels of 60% of
fresh controls after this LT approach.
For optimisation, David Pegg in
collaboration with Planer plc (a company
specializing in cryogenic engineering),
established an automatic pump and stirring
system for use within a controlled rate cryo-
cooler, which constantly increased the CPA
concentration whilst the temperature was
decreased. For the warming process normally
the reverse protocol is used by constantly
increasing the temperature whilst the CPA
concentration is reduced by dilution.
APPRAISAL OF THE MANUAL
APPROACH TO LT FOR
LABORATORY STUDIES
Manual Liquidus Tracking holds some
logistical advantages in that it does not require
complex equipment, and pre-set CPA solutions
can be prepared before the start of the procedure.
It can allow small batch vitrification for
moderate volumes (in the region of 2 – 10 ml),
and can help in testing various LT conditions in
parallel within one experiment (e.g. buffers,
AntiFreeze Proteins, antioxidants, CPAs) which
might be used to optimize LT. However, it is
demanding and requires close attention to the
various steps within LT, is limited by some
cryo-physical properties, and thus is liable to
higher operator-induced variabilities. We have
defined three test set-ups which can be used to
perform manual Liquidus Tracking.
LT Set-up 1- sample transfer between different
containers during cooling.
Set-up 1 corresponds to the manual LT
approach used by Farrant (6), Elford (3) and
Pegg (14). A series of pre-set low temperature
baths can be used to cool the samples step-wise
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with the appropriate CPA solutions loaded into
containers at each temperature to avoid ice
nucleation. The sample to be vitrified is
transferred from one sample container to the
next, each with a higher CPA concentration and
at a lower temperature, with a hold-period at
each time to allow sufficient CPA penetration
(Although objective evidence of this time period
is currently lacking, a general range can be
gleaned from previous studies (14). This set-up
is only suitable for tissue pieces, which can be
transferred by using forceps or encapsulated
cells of a unit size allowing them to be trapped
by a suitable cell strainer in which the sample
can be transferred. The necessary increase in
CPA can be calculated, and the CPA
concentration can be measured using a
refractometer to ensure the correct value has
been reached. (19) – e.g. see Figure 2.
In contrast, when using a controlled rate
freezer, all samples and solutions can be placed
into the freezer chamber at the start of the run at
fixed temperatures the cooling chamber has to
be opened to transfer the sample to the next
higher CPA solution. Samples can be processed
for example in 6-well plates. Possible
temperatures, at which the transfer can be
carried out when using Me2SO are -5°C (from
20% to 30% v/v CPA), -10°C (from 30% to 40%
CPA), -20°C (from 40% to 50% CPA), -30°C
(from 50% to 60% CPA) and -40°C (from 60%
to 70% CPA) using v/v Me2SO. The transfer
temperature includes an offset of approximately
+30% from the actual calculated Tm of the
sample to prevent any potential freezing. A
schematic of set-up 1 is shown in Figure 3 and
Table 1. The lowest temperature which can be
chosen for the transfer is determined by the CPA
concentration of the starting plate as it contains
the lowest CPA concentration. Subject to the
volume of CPA mix used for each sample step,
the cooling rate in the sample (as opposed to the
chamber) can become very slow when the
sample temperature gets close to the next hold-
step/transfer temperature. This was detected by
placing thermocouples into dummy wells. To
overcome this, the freezer temperature can be set
a few degrees below the desired transfer
temperature; however, this risks potential ice
nucleation if the process drifts too far away from
the liquidus curve. This risk can be mitigated by
recording temperatures from the thermocouples
in the dummy wells, and monitoring the progress
of cooling. In our case the freezer holding
temperature was set -10 degrees below the
planned transfer temperature to allow sufficient
cooling with a holding time of 10 minutes and a
freezer cooling rate of -2°C/min. This was used
to allow approximately 30 minutes between each
stepwise CPA increase. The sample volume was
8 ml per well for a 6-well plate set-up. The
incubation time was chosen on the basis of
Pegg’s work on articular cartilage (20). Cell
densities of alginate encapsulated HepG2 liver
cells are lower than those for articular cartilage
and therefore it was assumed that sufficient time
for CPA penetration was allowed. To process all
samples at the same freezer temperature, the
freezer had to be set on hold-in our studies for
10 minutes. The hold depends on how fast the
transfer temperature can be reached, how many
samples have to be processed and how much
time should be given for CPA penetration.
Depending on the experiment 6, 12 or 24 well
plates may be used, but CPA diffusion and heat
transfer parameters might vary and should be
tested.
One disadvantage of this approach can be
a solution carry-over effect which occurs each
time the samples are transferred in the cell
strainer to the next higher CPA concentration
and results from surface adherence of residual
CPA solution from the lower concentration on
the cell strainer or accumulated cell capsules
tissue pieces. This results in an uncontrolled and
successively increasing dilution of the CPA
solutions which might cause sample-to-sample
variability, and at worst might lead to ice
formation as lower temperatures are reached. In
addition, manual moving of the samples during
the transfer can cause inadvertent and variable
Figure 2. The refractive index of an aqueous
solution (Me2SO in 1x PBS at 20°C) as a
function of increasing CPA concentrations. By
using the standard curve (R=0.9993) the CPA
concentration of a sample can be determined.
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warming, depending on how fast the sample can
be moved to the next CPA well.
When using a controlled rate freezer (e.g.
cooled by circulating vapour generated by the
injection of liquid nitrogen), it should be
checked that all positions within the freezer
(close to circulation fan) and within the plate
(middle or corner) provide the same cooling rate,
as inhomogeneous heat transfer between the
wells can lead to sample-to-sample variability;
random ice formation in some samples was
visually noted in our experiments.
LT Set-up 2 – adding volumes of increasingly
higher CPA solutions in a single container
When using set-up 2 the sample remains
in the same sample container throughout the LT
vitrification procedure. For each incremental
cooling step, the CPA concentration is increased
by the addition of a higher concentration CPA
solution to achieve the required LT threshold
concentration. For example to increase the
concentration by increments of 10%, an equal
volume of a 20% absolute higher concentrated
CPA solution can be added. However, one noted
disadvantage is the increase in total CPA volume
as each additional step is made. This risk can be
mitigated before the next CPA addition by
reducing the sample volume e.g by pipetting off
half the volume once the cell material has
settled. Without this supernatant reduction step,
the volume might exceed the original tube
capacity but will certainly exceed the volume
that can be manually mixed at low temperatures,
without drastically increasing the temperature of
the sample, a result of the mixing procedure
itself. Besides the mixing difficulties, the
cooling rate profiles and properties of the sample
would change dramatically over the incremental
steps of the protocol. It can be recommended
from personal observations that for these
reasons, the volume to be mixed should not
exceed more than 6 ml in the final step. A
schematic of set-up 2 is shown in Figure 4.
As the volume has to be reduced, this set-
up is only feasible for sample material that will
accumulate at the bottom of the tube by gravity
(in the time given until the next CPA addition
step). Otherwise special filter tips/ transfer
processes have to be developed which may be
quite cumbersome (assuming that the tissues or
entrapped cells sediment by gravity), and will
again interfere with mixing. At the beginning of
the run enough CPA solutions of e.g. 40% 50%,
60%, 70% and 80% CPA have to be stored
within the freezer to be cooled. The volume of
each solution should be similar to the sample
volume to assure corresponding cooling rates.
The advantage of this approach is that the
sample remains within the same sample holder
during the whole LT process and the sample is
mixed during each step. The cooling rate will be
similar to the cooling rate of the freezer
chamber, especially when microfuge tubes and
volumes below 1 ml are used, and therefore the
hold temperatures of the cooling profile can be
equal to the desired transfer temperature. The
time the freezer has to be set on hold will
therefore mainly depend on number of samples
within the run, and CPA diffusion parameters at
low temperatures (although as stated already,
little objective information exists for this). To
allow a diffusion period of approximately 30
minutes and to provide a similar cooling profile
as for set-up 1, the holding temperature was first
set at the average temperature between the
Table 1. Scheme of possible temperatures at
which the transfer can be carried out when
using Me2SO.
% (v/v)
Me2SO
from:
transfer
at:
melting point
of Me2SO at:
freezer holding
temperature
20 to 30 -5°C 20%: -8°C -15°C
30 to 40 -10°C 30%: -15°C -20°C
40 to 50 -20°C 40%: -30°C -30°C
50 to 60 -30°C* 50%: -50°C -40°C
60 to 70 -40°C* N/A -50°C
*transfer temperatures were determined
empirically, as viscosities at colder
temperatures are too difficult to handle. N/A
states for non-applicable.
Figure 3. A schematic showing samples (in cell strainers)
being transferred between 6 well plates with increasing
CPA concentration (e.g. 20% 30%, 40%, 50%, 60% and
70% Me2SO) as the cooling proceeds. All plates are placed
into the freezer at the beginning of the run. Possible
temperatures at which the change can be carried out when
using Me2SO are -5°C (from 20% to 30%), -10°C (from
30% to 40%), -20°C (from 40% to 50%), -30°C (from 50%
to 60%) and -40°C (from 60% to 70%) (v/v) Me2SO.
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starting and the transfer temperature for 15
minutes. Then an additional holding step was set
at 5°C below the transfer temperature for 7
minutes to reach the required temperature and to
process the samples. As for set-up 1, a freezer
cooling rate of -2°C/min was chosen.
The primary disadvantage of set-up 2 is
the difficulty of maintaining the temperature
whilst CPA concentration is changed. As the
freezer chamber is opened to allow manual
access, the temperature inside the freezer may
deviate rapidly, affecting the temperature of the
solutions kept inside the freezer. Extracting and
adding half of the sample volume and the mixing
process takes time and will impact the sample
temperature depending on its volume, with small
volumes being more easily subject to
temperature fluctuation. For our feasibility
study, 2 ml microfuge tubes were used with a
maximum volume of 1.5 ml. During the CPA
addition processes a temperature increase of up
to +20°C was measured by thermocouples
placed in sample tubes. A second disadvantage
might be the numbers of tubes with different
CPA solutions that have to be kept in the freezer
which can be complicated when comparing
different conditions within the same run.
LT Set-up 3 – based on use of one highly
concentrated CPA solution to provide required
concentration increase.
Set-up 3 is a variant of LT set-up 2
whereby only one highly concentrated CPA
solutions is used to make the stepwise required
CPA concentration. Since the final steps of LT
require solutions in the range of 60% CPA, an
extremely concentrated CPA (80% v/v) is
needed to achieve this goal. One advantage of
set-up 3 is that only smaller volumes need to be
added at each step, avoiding the problem of
accumulating supernatant volumes, and
therefore the sample volume does not have to be
reduced each time as for set-up 2. Several other
advantages can be outlined for this approach: as
only one solution has to be added the accuracy
of achieving the target CPA improves; there is
no loss of cell material and the process is faster
which means less sample-to-sample variability
due to potential temperature variation. The
average temperature increase during each CPA
addition and mixing step in our experiments was
determined to be approximately +11°C. Even so,
heat transfer for the steps in set-up 3 is slightly
different as volumes change, but nevertheless
the same holding time and temperatures were
used on a pragmatic basis. A schematic of set-up
3 is shown in Figure 5 and Table 2.
A disadvantage is that highly concentrated
CPA is added to the sample at relatively high
temperatures which could be a problem for cells
that are especially prone to osmotic stress and
CPA toxicity if the mixing is not quick enough.
As a compromise two different high
concentrated solutions could be used, e.g. with a
concentration of 60% for the first steps and 80%
final increase. Even though the final volume is
limited to 5-6 ml, mixing still might become
difficult during the last steps depending on the
CPAs used and their low-temperature
viscosities.
Figure 4. A schematic of set-up 2. CPA
concentration by increments of 10% is
increased by adding an equal amount of a 20%
higher concentrated CPA solution. After
mixing, the volume is reduced. The same
transfer temperatures as for set-up 1 (Table 1)
can be used.
Figure 5. A schematic of set-up 3. One highly
concentrated CPA solutions (80%) increases
the CPA concentration of the sample. Smaller
volumes have to be added to increase the
sample CPA concentration so sample volume
does not have to be reduced after each addition
as for set-up 2.
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WARMING
The equally important principle of LT is
that a reverse process is essential, where the high
CPA concentrations are reduced, at intermediate
subzero temperatures sufficient to be above the
liquidus curve, again in a progressive or step-
wise manner, as the samples progress back up
the temperature scale. If only one controlled rate
freezer is available it is recommended to use
only two different temperatures steps.
Differently concentrated CPA solutions cannot
be cooled down within the same freezer if the
freezer temperature is kept close to the melting
temperature of the sample, otherwise they will
freeze. This may be overcome if multiple low
temperature baths are available. For example,
according to the liquidus curve a sample of 50%
Me2SO (v/v) should be kept at approximately -
39°C. A 40% Me2SO solution for the dilution
has to be kept above -23°C and a solution of
30% above -14°C. The temperature closest to the
sample liquidus curve that can be used for the
first dilution would therefore be -23°C; a
temperature at which the 30% CPA solution
would already nucleate. This can be overcome
by raising the freezer temperature after each
dilution step before placing the next more dilute
solution into the freezer. However it will take
time for the dilution solution to cool down to the
freezer temperature from approximately 0°C
when kept on ice. Therefore the warming
process might take several hours resulting in
longer exposure times to CPA and cold storage.
Given the limits of manual practicalities and the
need to reduce the potentially-toxic levels of
CPA, a two-step procedure might therefore be
the better choice. For example the freezer could
be set to -20°C and all dilution steps to 40%
CPA (depending on the CPAs used) could be
done at that temperature. The second step could
then be done on ice with a CPA decrease to
directly 0%, advisably by using an osmotic
buffer. To reduce the sample CPA
concentration, more dilute CPA can either be
added to the same tube or the sample can be
poured through a cell strainer and then
transferred to a less concentrated CPA solution.
Adding CPA to the sample means substantially
increasing the sample volume and this has to be
reduced either by using a filter system (cell
strainer or pipette tips with filter) or by
gravitation and removal of the supernatant. CPA
solutions can be very viscous at low
temperatures and samples may need to be
diluted before using any type of filter system.
Also tissue pieces or encapsulated cell beads
might stick to the tube wall when transferring to
a cell strainer, resulting in loss of starting
material. A wash step with CPA solution at
subzero temperatures can be performed to
mitigate this. Depending on how susceptible
cells are to osmotic stress and CPA toxicity,
either the faster method or the method that
maintains the sample temperature closest to the
melting point can be chosen.
FEASABILITY STUDIES – RESULTS
CONCERNING MANUAL LIQUIDUS
TRACKING
In an initial experiment we investigated
the concept that CPA toxicity can indeed be
reduced at subzero temperatures when applying
the highly concentrated CPA needed for LT.
Therefore alginate encapsulated liver cells,
cultured for 4-5 days were incubated at 37°C
(incubator), 20°C (room temperature), 4°C
(fridge), -10°C and -20°C (Planer Kryo 10
freezer) for 40 minutes in increasing
concentrations of Me2SO (Figure 6). Beads
incubated at -10°C and -20°C were pre-
incubated for 1 min at 0.5°C (ice water) in 20%
(v/v) and 30% (v/v) Me2SO, respectively. This
was done to prevent immediate intra- and
extracellular freezing of the cells once the
sample was exposed to subzero temperatures.
Table 2. Amount of 80% v/v CPA that has to
be added to increase the sample CPA
concentration by increments of 10%
Initial
CPA (%)
Initial
Vol. (µl)
Vol. (µl) of
80% CPA
to add
Target
CPA (%)
20 750 150 30
30 900 225 40
40 1125 375 50
50 1500 750 60
60 2250 2250 70
final vol. 4500
Formula to determine the amount of 80%
CPA to be added: B=(A*c-A*a)/(b-c) with
B=vol. of 80% CPA to add, A=start vol.,
c=final CPA concentration, a=start CPA
concentration, b=80% CPA
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After the incubation, beads were washed with
1xPBS (Mg2+, Ca2+) and viability was measured
as described previously (12). The lower the
incubation temperature, the higher was the
remaining viability. Up to 50% (v/v) Me2SO was
well tolerated when alginate encapsulated
HepG2 cells were incubated at -20°C but
dropped to 0% for all higher temperatures
between -10°C and +37°C.
In order to investigate at which step
viability was mostly decreased during the LT
procedure, step-by-step LT experiments were
carried out (Figure 7). All three set-ups; 1, 2 and
3 (described above) were tested. The steps were
chosen to cover the incremental increase in CPA
concentration and cooling, down to the point
where the vitreous transformation would be
predicted (see Figure 7). Some samples were
removed at each stage just before the next
addition of Me2SO, and rewarmed for viability
measurements, whilst the remaining cohort
stayed in the controlled rate freezer as the LT
run progressed further. In brief, (1) at -5°C, (2)
the 20% Me2SO solution with alginate
encapsulated beads was increased to 30%
Me2SO with mixing; this was then repeated (3)
at -10°C with increase to 40% Me2SO, (4) at -
20°C with increase to 50% Me2SO, (5) at -30°C
to 60% Me2SO and (6) at -40°C to 70% v/v
Me2SO. Between each CPA addition, 30 minutes
were allowed for cooling and CPA change-(see
set-ups 1-3). In the final step (7), two of the two
remaining samples were slowly cooled down to -
60°C. One sample was warmed up immediately;
the other one was directly added to the vapour
phase of liquid nitrogen where it was stored for
3-7 days before warming. For the complete LT
pathway, the time taken to achieve the vitrified
state was about 150 minutes. A simplified
reversal of the LT protocol was used to warm
samples after cooling. To avoid osmotic injury
during dilution, the Me2SO increase per step was
limited to a 30% (v/v) concentration reduction.
Samples with a Me2SO concentration of 20-30%
(v/v) were placed directly into (1) ice-cold
1xPBS (Sigma, Mg2+, Ca2+) for 10 minutes, then
washed several times with 1xPBS, transferred to
complete media and incubated at 37°C. Samples
with a final concentration of 40-50% (v/v)
Me2SO were placed into ice-cold 20% (v/v)
Me2SO for 10 minutes and were then processed
as described in (1). Samples at 60% (v/v)
Me2SO and samples at 70% (w/w) Me2SO at -
60°C were first placed into 40% (v/v) Me2SO at
-20°C for 15 minutes, then into ice-cold 20%
(v/v) Me2SO for 10 minutes and were then
processed as described in (1). Lastly, vitrified
samples stored at -160°C were transferred to -
80°C for 20 minutes and were then processed
equally to those samples simply cooled to -60°C.
For vitrified samples, the complete process of
reversed LT took approximately 1 hour. From
Figure 7 it is clear that viability was decreased
after each LT step, and thus the results did not
indicate a specific concentration at which
viability was primarily reduced. The data
suggest that viability is mainly reduced between
30% and 60% (v/v) Me2SO but remains constant
between 60% and 70% (v/v) Me2SO, regardless
of whether samples are cooled down to -60°C
and immediately re-warmed or stored at -160°C.
The experiments showed that cell viabilities can
be ~30% after achieving the vitrified state and
reversal via LT. To our knowledge, this is the
first report of viable cell recoveries using LT for
encapsulated cell organoids. The fact that
approximately two thirds of the functional cell
mass was lost during LT may seem
disappointing, but on the other hand, the results
indicate that a significant proportion of
mammalian cells can withstand controlled
vitrification by LT. It may be possible to
increase the survival by attention to detail in
each of the progressive steps of the overall LT
process.
Figure 6. Encapsulated cells were incubated at
increasing Me2SO concentrations at decreasing
temperatures, for 40 minutes. Up to 50% (v/v)
Me2SO was well tolerated when alginate
encapsulated HepG2 cells were incubated at -20°C,
showing that Me2SO toxicity (osmotic and
chemical) is reduced at lower temperatures.
Viability dropped to 0% when a certain Me2SO
concentration was reached. Viability was assessed
24h after rewarming using fluorescent vital dyes,
fluorescein diacetate and propidium iodide (11).
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Preliminary indications for improving
laboratory translation for manual LT: - better
control of temperature profiles.
Set-up number 3 has shown to be the most
practical in our hands. Nevertheless heat
fluctuation during the CPA addition process was
observed. The increase in sample temperature
was especially large at lower temperatures. This
was mainly caused by a prolonged mixing
procedure due to increasing sample viscosity and
the larger volumes to be mixed. One way to
provide a more reliable process during manual
LT could be by using a ‘thermal buffer- jacket -
TB’ – by placing each sample container (15 ml
centrifuge tube) within a 70% ethanol solution
held in a 50 ml centrifuge tube. The following
was considered necessary for a useful TB
system: the solution used for TB should not
freeze during the cooling or warming process as
this would affect the cooling rate of the LT
sample itself due to altered heat capacities. Also
the TB solution has to remain liquid so that the
LT sample tube can be taken out from the TB at
the end of the run and stored in liquid nitrogen.
Additionally, the TB system must be as
symmetrical as possible to allow a homogenous
cooling profile throughout the entire volume.
The toxicity of the TB carrier solution should
also be as low as possible for handling purposes,
and the TB should be of a size that can be fitted
within a controlled rate freezer (e.g. used here,
the Planer Kryo -10 freezer). The cooling rate of
the sample during the LT steps should be
affected as little as possible, while the TB
isolation should maintain the same temperature
for several minutes in an altered environment
until the CPA change has been processed. Other
combinations of TB carrier solutions and tubes
with better thermal buffering abilities might be
used. Nevertheless this will lead to lower sample
cooling rates causing longer runs and therefore
longer exposure times to CPAs and cold
temperatures. By using the described TB
isolation system the temperature fluctuation was
reduced from a maximum of +18°C (CPA
addition at -35°C) to less than + 5°C (n=3).
Additionally, handling variability can be
compensated for by testing a higher number of
samples. However the maximum number of
samples that can be processed during one LT run
has to be limited to maintain similar sample
warming and incubation times for all the
processed samples. Thus, in our experience, in
the present manual LT feasibility it was found
that the maximum number of samples per
experiment was 8, , all of which could be housed
in the chamber of a Kryo 10 cooler and
processed within 2 minutes, including CPA
addition and mixing.
DISCUSSION
The fundamental basis of LT theory
encompasses the concept that CPA toxicity can
be reduced if the temperature is decreased, such
that concentrations high enough to lead to
vitrification can be achieved step-by-step at
lower temperatures. This has been shown in
previous work by Matheny in 1968 (13) who
incubated rabbit atria in different Me2SO
concentrations at decreasing temperatures. The
effect is also reflected by reduced drug
efficiency at lower body temperature, which has
been widely studied by Weihe in 1973 (21).
Reduced toxicity and decreased drug efficiency
can be explained by decreased enzyme activity,
which for mammalian cells is highest at ~37°C,
and also a result of decreased reaction kinetics in
general, which includes reduced chemical and/or
osmotic stresses. This Liquidus Tracking (LT)
Figure 7. LT step-by-step: To determine at which
step viability is lost during the LT procedure a step-
by-step LT set-up was carried out. Therefore one
sample was taken out of the Planer freezer before
the Me2SO concentration was increased and
temperature further reduced for the remaining
samples. All three set-ups; 1, 2 and 3 were tested.
Considerable variability is seen between runs.
Nevertheless viability dropped mostly between 30%
and 60% Me2SO (v/v) (except for set-up 2).
Viability after incubation in 70% (v/v) Me2SO is
approximately 30% regardless of whether samples
were cooled to -60°C or cooled and stored at -
160°C. Viability was assessed 24h after rewarming
using fluorescent vital dyes, fluorescein diacetate
and propidium iodide (11). Data for set-up 1 was
n=4 +/-SD.
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principle was confirmed in our current work
(Figure 6) whereby incubating alginate
encapsulated liver cells in increasing
concentrations of Me2SO at temperatures
between 37°C and -20°C showed less injury at
lower temperatures. Nevertheless reduced
toxicity at lower temperatures does not assure
effective vitrification, since sufficient CPA has
to penetrate into the cells to avoid ice nucleation
before the temperature is further decreased. It is
possible that in these experiments cells
incubated at -10°C or -20°C did not reach the
same intra-cellular Me2SO concentration as cells
incubated at higher temperatures. For an
optimized liquidus tracking procedure it is
therefore necessary to compromise between
longer exposure time and higher exposure
temperature to achieve sufficient CPA
penetration, and shorter exposure time at lower
temperatures for minimum toxicity.
Three manual LT approaches were tested
and compared. Advantages and disadvantages
have been addressed in section 3. All three
methods showed a constant small but
progressive decrease in viability after each
Me2SO concentration increase. The data (Figure
7) suggests that viability was mainly reduced
between the steps from 30% to 60% (v/v)
Me2SO (except set-up 3) but thereafter remained
constant between 60% and 70% (v/v) Me2SO,
regardless of whether samples were cooled down
to -60°C and immediately re-warmed or vitrified
and stored at -160°C. An explication for this
could be that CPA concentrations up to 30%
(v/v) Me2SO are well tolerated for over 40
minutes when kept at 0.5°C (Figure 6).
Concentrations of 60% and 70% (v/v) Me2SO
are reached at very low temperatures (<-25°C)
and it could be hypothesized that at these low
temperatures, the Me2SO influx is limited so that
full intracellular Me2SO concentrations of 60-
70% (v/v) might not be achieved (which could
explain higher consistency between these steps).
In this respect, cells that survived the LT process
until the final increase to 70% (v/v) Me2SO
seem to have achieved sufficient Me2SO
penetration to be vitrified. This could of course
also be brought about by the high viscosities of
the Me2SO mixture acting to kinetically inhibit
ice crystal formation, and the parallel extreme
osmotic dehydration of the cells which also
prevented organisation of any residual water
molecules into ice nuclei. Further work will be
needed to investigate these possibilities.
However, morphologically it was possible to
visibly discern when ice nucleation had taken
place in individual samples which had not been
appropriately incubated in the early stages of the
feasibility study, particularly using these large
volumes. Thus we feel confident that we
managed to reproduce essential LT in our
selected protocols.
High variability between experiments can
be partially explained by temperature profile
variations and CPA concentration differences
between samples resulting from the different
manual approaches to achieving LT. Inter-
sample temperature differences for set-up 1 may
have been caused by the sample position within
the freezer, the differing thermal masses of
different LT receptacles – e.g. position in the 6-
well plate (corner or middle) and time taken to
change the CPA concentration. Divergent CPA
concentrations across the LT steps could have
resulted from pipetting difficulties with the
highly viscous higher CPA solutions, and ‘carry
over’ effects in those experiments where
samples were physically moved between
different Me2SO mixtures. In our experience,
set-up 3 was the most easily and consistently
achieved LT protocol when considering all the
logistical hurdles. Higher post-warming
viabilities and performance can be expected for
further improvements in the manual LT method.
Reduced temperature fluctuations (by using
thermal buffering of individual samples) and
improved CPA addition and mixing steps (by
seeking better mixers) should help to make the
change.
CONCLUSION
LT by manual protocols has been shown
to be a complex and lengthy procedure, but it
does allow larger volumes to be stored in the
vitrified state when only slow cooling rates can
be achieved. For example, given the number of
samples which could be handled in our set-up 3
(up to 8 tubes with 5 ml in each) a biomass of
about 40 ml could be vitrified in one run, which
is far higher than could be considered for the
same materials if traditional vitrification
methods were applied (samples <100 µl plus and
ultra-rapid cooling). Some of the complications
that were observed for manual LT may not apply
for an optimized automatic approach, which
would minimize inhomogeneous Me2SO
concentrations and temperature fluctuations
during step Me2SO changes. Moreover the
Me2SO concentration will potentially be
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increased in smaller steps and therefore toxicity
and osmotic effects should be further reduced. In
addition, by its nature, manual liquidus tracking
is complicated and can result in high variability.
Nevertheless, this approach offers the possibility
of testing several conditions at the same time
and could therefore be used to pre-test different
LT factors before being taken forward to
automatic LT. Using a combination of
penetrating and non-penetrating CPAs, instead
of Me2SO as a sole reagent, combined with the
improvements in manual set-ups, should offer
further improvements in post-warming viable
cell recoveries.
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